Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines

William A. Herzer, Neal J. Thomas, Joseph A. Carcillo, Stevan P. Tofovic, Edwin K. Jackson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Type IV phosphodiesterase (PDE4) inhibitors may be useful in several diseases in which catecholamine infusions are commonly used, including asthma, sepsis, and multiple organ failure. To determine whether type IV phosphodiesterase inhibitors alter baseline or catecholamine-induced changes in cardiac function or both, we examined the effects of Ro 20-1724 (PDE4 inhibitor) on several cardiac-performance parameters in the absence and presence of norepinephrine, epinephrine, isoproterenol, and dobutamine infusions (3, 1, 0.1, and 3 μg/kg/min, respectively). Male Sprague-Dawley rats received either Ro 20-1724 (10 μg/kg/min; n = 7) or vehicle (n = 6). After a left ventricular catheter was placed and connected to a heart- performance analyzer, each animal received each of the four catecholamines in randomized order (10 min per catecholamine with a 30-min washout period between infusions). In the absence of catecholamines, Ro 20-1724 significantly but mildly (i.e., <10%) increased heart rate but did not alter significantly any other measured cardiac parameter. In addition, Ro 20-1724 did not significantly alter norepinephrine-, epinephrine-, or dobutamine- induced changes in cardiac-performance parameters. There was, however, a significant attenuation of the isoproterenol-induced increase in a single measure of cardiac contractility (maximum dP/dt normalized to pressure). PDE4 inhibition does not cause significant cardiac toxicities in rats, both in the absence and presence of catecholamines. Our data suggest that PDE4 inhibitors may be safely used in critically ill patients receiving catecholamines. A clinical trial of this family of drugs in patients with critical illness is now being planned.

Original languageEnglish (US)
Pages (from-to)769-776
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume32
Issue number5
DOIs
StatePublished - Nov 1 1998

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
Catecholamines
Phosphodiesterase 4 Inhibitors
Dobutamine
Phosphodiesterase Inhibitors
Isoproterenol
Critical Illness
Epinephrine
Norepinephrine
Multiple Organ Failure
Sprague Dawley Rats
Sepsis
Asthma
Catheters
Heart Rate
Clinical Trials
Pressure

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Herzer, William A. ; Thomas, Neal J. ; Carcillo, Joseph A. ; Tofovic, Stevan P. ; Jackson, Edwin K. / Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. In: Journal of Cardiovascular Pharmacology. 1998 ; Vol. 32, No. 5. pp. 769-776.
@article{00c9cb3916534b3db7add535a5323b54,
title = "Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines",
abstract = "Type IV phosphodiesterase (PDE4) inhibitors may be useful in several diseases in which catecholamine infusions are commonly used, including asthma, sepsis, and multiple organ failure. To determine whether type IV phosphodiesterase inhibitors alter baseline or catecholamine-induced changes in cardiac function or both, we examined the effects of Ro 20-1724 (PDE4 inhibitor) on several cardiac-performance parameters in the absence and presence of norepinephrine, epinephrine, isoproterenol, and dobutamine infusions (3, 1, 0.1, and 3 μg/kg/min, respectively). Male Sprague-Dawley rats received either Ro 20-1724 (10 μg/kg/min; n = 7) or vehicle (n = 6). After a left ventricular catheter was placed and connected to a heart- performance analyzer, each animal received each of the four catecholamines in randomized order (10 min per catecholamine with a 30-min washout period between infusions). In the absence of catecholamines, Ro 20-1724 significantly but mildly (i.e., <10{\%}) increased heart rate but did not alter significantly any other measured cardiac parameter. In addition, Ro 20-1724 did not significantly alter norepinephrine-, epinephrine-, or dobutamine- induced changes in cardiac-performance parameters. There was, however, a significant attenuation of the isoproterenol-induced increase in a single measure of cardiac contractility (maximum dP/dt normalized to pressure). PDE4 inhibition does not cause significant cardiac toxicities in rats, both in the absence and presence of catecholamines. Our data suggest that PDE4 inhibitors may be safely used in critically ill patients receiving catecholamines. A clinical trial of this family of drugs in patients with critical illness is now being planned.",
author = "Herzer, {William A.} and Thomas, {Neal J.} and Carcillo, {Joseph A.} and Tofovic, {Stevan P.} and Jackson, {Edwin K.}",
year = "1998",
month = "11",
day = "1",
doi = "10.1097/00005344-199811000-00013",
language = "English (US)",
volume = "32",
pages = "769--776",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. / Herzer, William A.; Thomas, Neal J.; Carcillo, Joseph A.; Tofovic, Stevan P.; Jackson, Edwin K.

In: Journal of Cardiovascular Pharmacology, Vol. 32, No. 5, 01.11.1998, p. 769-776.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines

AU - Herzer, William A.

AU - Thomas, Neal J.

AU - Carcillo, Joseph A.

AU - Tofovic, Stevan P.

AU - Jackson, Edwin K.

PY - 1998/11/1

Y1 - 1998/11/1

N2 - Type IV phosphodiesterase (PDE4) inhibitors may be useful in several diseases in which catecholamine infusions are commonly used, including asthma, sepsis, and multiple organ failure. To determine whether type IV phosphodiesterase inhibitors alter baseline or catecholamine-induced changes in cardiac function or both, we examined the effects of Ro 20-1724 (PDE4 inhibitor) on several cardiac-performance parameters in the absence and presence of norepinephrine, epinephrine, isoproterenol, and dobutamine infusions (3, 1, 0.1, and 3 μg/kg/min, respectively). Male Sprague-Dawley rats received either Ro 20-1724 (10 μg/kg/min; n = 7) or vehicle (n = 6). After a left ventricular catheter was placed and connected to a heart- performance analyzer, each animal received each of the four catecholamines in randomized order (10 min per catecholamine with a 30-min washout period between infusions). In the absence of catecholamines, Ro 20-1724 significantly but mildly (i.e., <10%) increased heart rate but did not alter significantly any other measured cardiac parameter. In addition, Ro 20-1724 did not significantly alter norepinephrine-, epinephrine-, or dobutamine- induced changes in cardiac-performance parameters. There was, however, a significant attenuation of the isoproterenol-induced increase in a single measure of cardiac contractility (maximum dP/dt normalized to pressure). PDE4 inhibition does not cause significant cardiac toxicities in rats, both in the absence and presence of catecholamines. Our data suggest that PDE4 inhibitors may be safely used in critically ill patients receiving catecholamines. A clinical trial of this family of drugs in patients with critical illness is now being planned.

AB - Type IV phosphodiesterase (PDE4) inhibitors may be useful in several diseases in which catecholamine infusions are commonly used, including asthma, sepsis, and multiple organ failure. To determine whether type IV phosphodiesterase inhibitors alter baseline or catecholamine-induced changes in cardiac function or both, we examined the effects of Ro 20-1724 (PDE4 inhibitor) on several cardiac-performance parameters in the absence and presence of norepinephrine, epinephrine, isoproterenol, and dobutamine infusions (3, 1, 0.1, and 3 μg/kg/min, respectively). Male Sprague-Dawley rats received either Ro 20-1724 (10 μg/kg/min; n = 7) or vehicle (n = 6). After a left ventricular catheter was placed and connected to a heart- performance analyzer, each animal received each of the four catecholamines in randomized order (10 min per catecholamine with a 30-min washout period between infusions). In the absence of catecholamines, Ro 20-1724 significantly but mildly (i.e., <10%) increased heart rate but did not alter significantly any other measured cardiac parameter. In addition, Ro 20-1724 did not significantly alter norepinephrine-, epinephrine-, or dobutamine- induced changes in cardiac-performance parameters. There was, however, a significant attenuation of the isoproterenol-induced increase in a single measure of cardiac contractility (maximum dP/dt normalized to pressure). PDE4 inhibition does not cause significant cardiac toxicities in rats, both in the absence and presence of catecholamines. Our data suggest that PDE4 inhibitors may be safely used in critically ill patients receiving catecholamines. A clinical trial of this family of drugs in patients with critical illness is now being planned.

UR - http://www.scopus.com/inward/record.url?scp=0031766265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031766265&partnerID=8YFLogxK

U2 - 10.1097/00005344-199811000-00013

DO - 10.1097/00005344-199811000-00013

M3 - Article

C2 - 9821851

AN - SCOPUS:0031766265

VL - 32

SP - 769

EP - 776

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 5

ER -